Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Phase Ⅳ Clinical Trial to Evaluate the Immunity Persistence After Single Dose of 23-valent Pneumococcal Polysaccharide Vaccine

NCT04989465 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.

NCT NCT04989465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Phase Ⅳ Clinical Trial to Evaluate the Immunity Persistence After Single Dose of 23-valent Pneumococcal Polysaccharide Vaccine
Lead sponsor
Sinovac Biotech Co., Ltd
Phase
Phase 4
Overall status
Completed
Start date
September 10, 2021
Completion date
September 13, 2021
Enrollment
600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infections